Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

374.47
+5.311.44%
Post-market: 374.470.00000.00%19:30 EDT
Volume:252.60K
Turnover:95.12M
Market Cap:42.69B
PE:67.00
High:379.48
Open:375.00
Low:374.37
Close:369.16
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:85.69M
Volume Ratio:0.59
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:8.25
PE(LYR):151.61

Loading ...

BEIGENE Grants 17,700 Restricted Stock Units in Form of ADSs

Stock News
·
Apr 08

Truist Financial Remains a Buy on BeOne Medicines (ONC)

TIPRANKS
·
Apr 06

Is BeOne Medicines (ONC) Pricing In Too Much Optimism After Recent Share Price Drop?

Simply Wall St.
·
Mar 25

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

TIPRANKS
·
Mar 18

Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)

TIPRANKS
·
Mar 17

BeOne Medicines Cut to Hold From Buy by Jefferies

Dow Jones
·
Mar 16

Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness

Simply Wall St.
·
Mar 15

BEIGENE Allots 741,300 Shares Under Equity Incentive Plan

Stock News
·
Mar 12

BEIGENE Announces New Enrollment Period for 2018 Employee Stock Purchase Plan

Stock News
·
Mar 10

BeiGene Grants Restricted Stock Units Equivalent to 21,200 ADSs

Deep News
·
Mar 08

BEIGENE Grants 21,200 Restricted Stock Units in the Form of ADSs

Stock News
·
Mar 06

First Batch of Companies Set to Exit STAR Market Growth Layer, Including Cambricon and Beigene

Deep News
·
Mar 06

BeOne Medicines Pharma Alliances Contrast With High P/E And Valuation Upside

Simply Wall St.
·
Mar 05

Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand

Stock Track
·
Mar 03

Assessing BeOne Medicines (NasdaqGS:ONC) Valuation After Its Recent Rebrand And Share Price Weakness

Simply Wall St.
·
Mar 03

BofA International Maintains Buy Rating on BEIGENE Following Robust Product Sales Performance

Stock News
·
Mar 03

BEIGENE Retains "Buy" Rating from Guojin Securities as Early-Stage Pipeline Nears Harvest

Stock News
·
Mar 03

Beone Medicines : Leerink Partners Cuts Target Price to $364 From $370

THOMSON REUTERS
·
Feb 27

Guggenheim Keeps Their Buy Rating on BeOne Medicines (ONC)

TIPRANKS
·
Feb 27

BeOne Medicines (ONC) Receives a Buy from RBC Capital

TIPRANKS
·
Feb 27